Cover Image
市場調查報告書

Mirna Therapeutics, Inc.:產品平台分析

Mirna Therapeutics, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 199741
出版日期 內容資訊 英文 34 Pages
訂單完成後即時交付
價格
Back to Top
Mirna Therapeutics, Inc.:產品平台分析 Mirna Therapeutics, Inc. - Product Pipeline Review - 2015
出版日期: 2015年02月28日 內容資訊: 英文 34 Pages
簡介

Mirna Therapeutics, Inc.ha是研究·開發利用miRNA的癌症治療產品之生物醫藥品企業。

本報告提供Mirna Therapeutics, Inc.的治療藥開發平台現狀及各開發階段的比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,彙整最新的企業新聞和發表,後期階段及中止的計劃相關資訊等。

Mirna Therapeutics, Inc.的基本資料

Mirna Therapeutics, Inc.概要

  • 主要資訊
  • 企業資料

Mirna Therapeutics, Inc.:R&D概要

  • 主要的治療範圍

Mirna Therapeutics, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Mirna Therapeutics, Inc.:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Mirna Therapeutics, Inc.:藥物簡介

  • MRX-34
  • Mir-Rx01
  • miR-Rx02
  • MiR-Rx03
  • MiR-Rx06
  • MiR-Rx07
  • mIR-Rx16
  • MiR-Rxlet-7

Mirna Therapeutics, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型

Mirna Therapeutics, Inc.:最近的開發平台趨勢

Mirna Therapeutics, Inc.:暫停中的計劃

Mirna Therapeutics, Inc.:總公司和子公司的所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06840CDB

Summary

Global Markets Direct's, 'Mirna Therapeutics, Inc. - Product Pipeline Review - 2015', provides an overview of the Mirna Therapeutics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Mirna Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Mirna Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Mirna Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Mirna Therapeutics, Inc.'s pipeline products

Reasons to buy

  • Evaluate Mirna Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Mirna Therapeutics, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Mirna Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Mirna Therapeutics, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Mirna Therapeutics, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Mirna Therapeutics, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Mirna Therapeutics, Inc. Snapshot
    • Mirna Therapeutics, Inc. Overview
    • Key Information
    • Key Facts
  • Mirna Therapeutics, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Mirna Therapeutics, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Mirna Therapeutics, Inc. - Pipeline Products Glance
    • Mirna Therapeutics, Inc. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Mirna Therapeutics, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Mirna Therapeutics, Inc. - Drug Profiles
    • MRX-34
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • let-7 + miR-34
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • miR-Rx06
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • miR-Rx07
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • mIR-Rx16
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • miR-Rxlet-7
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Mirna Therapeutics, Inc. - Pipeline Analysis
    • Mirna Therapeutics, Inc. - Pipeline Products by Target
    • Mirna Therapeutics, Inc. - Pipeline Products by Route of Administration
    • Mirna Therapeutics, Inc. - Pipeline Products by Molecule Type
  • Mirna Therapeutics, Inc. - Recent Pipeline Updates
  • Mirna Therapeutics, Inc. - Dormant Projects
  • Mirna Therapeutics, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Mirna Therapeutics, Inc., Key Information
  • Mirna Therapeutics, Inc., Key Facts
  • Mirna Therapeutics, Inc. - Pipeline by Indication, 2015
  • Mirna Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • Mirna Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • Mirna Therapeutics, Inc. - Combination Treatment Modalities in Pipeline, 2015
  • Mirna Therapeutics, Inc. - Partnered Products in Pipeline, 2015
  • Mirna Therapeutics, Inc. - Partnered Products/ Combination Treatment Modalities, 2015
  • Mirna Therapeutics, Inc. - Phase I, 2015
  • Mirna Therapeutics, Inc. - Preclinical, 2015
  • Mirna Therapeutics, Inc. - Discovery, 2015
  • Mirna Therapeutics, Inc. - Pipeline by Target, 2015
  • Mirna Therapeutics, Inc. - Pipeline by Route of Administration, 2015
  • Mirna Therapeutics, Inc. - Pipeline by Molecule Type, 2015
  • Mirna Therapeutics, Inc. - Recent Pipeline Updates, 2015
  • Mirna Therapeutics, Inc. - Dormant Developmental Projects,2015

List of Figures

  • Mirna Therapeutics, Inc. - Pipeline by Top 10 Indication, 2015
  • Mirna Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • Mirna Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • Mirna Therapeutics, Inc. - Partnered Products in Pipeline, 2015
  • Mirna Therapeutics, Inc. - Pipeline by Top 10 Target, 2015
  • Mirna Therapeutics, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Mirna Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2015
Back to Top